Biosimilars entry and price development in Europe

In light of the increasing interest in pricing and entry of biosimilars in Europe, this research has found that the market of filgrastim biosimilars is dominated by the entry effect, while that of epoetins is driven by the competition effect. The epoetins market gets saturated relatively faster in terms of number of local competitors, which can be explained by the molecular complexity of that medicine. For both filgrastim and epoetins, the effect of biosimilar prices on originator prices is weak. This outcome is amplified by the impossibility of direct substitution for biosimilars in Europe.